ABUS 241220 2.50C (ABUS241220C2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ABUS241220C2500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 27 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Arbutus BiopharmaNov 26 00:00 ET
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
BenzingaNov 20 07:45 ET
Chardan Capital Maintains Buy on Arbutus Biopharma, Raises Price Target to $5
BenzingaNov 20 05:58 ET · Ratings
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5
Moomoo NewsNov 19 21:32 ET · Ratings
Arbutus Biopharma Analyst Ratings
BenzingaNov 18 07:16 ET · Ratings
Express News | Barinthus Biotherapeutics Shares Are Trading Lower. The Company Announced Data From the Ongoing Phase 2b HBV003 Clinical Trial
BenzingaNov 15 13:19 ET

Comments

Jaguar8

Nov 15 10:05

ADDED NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Arbutus Biopharma (ABUS) announced promising results from its IM-PROVE I Phase 2a clinical trial for imdusiran, its RNAi therapeutic for chronic hepatitis B virus (cHBV).
When combined with 24 weeks of pegylated interferon and nucleos(t)ide analogue therapy, the treatment achieved a 50% functional cure rate (3/6 patients) in patients with baseline ...

Jaguar8

Nov 15 10:02

NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial for chronic hepatitis B treatment.
The study evaluated the combination of imdusiran, VTP-300, and low-dose nivolumab.
Key findings show that 23% of participants receiving the triple combinati...

Jaguar8

Oct 15 07:58

NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Arbutus Biopharma (Nasdaq: ABUS) announced that clinical data for imdusiran, an RNAi therapeutic for chronic hepatitis B virus (cHBV) infection, will be presented in four posters at the AASLD - The Liver Meeting® 2024. Two late-breaking posters will feature data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials.
Key findings fr...

Trytosaveabit

Aug 1 06:56

Update

$Arbutus Biopharma (ABUS.US)$ Trading quotes resume at 7:55 and trading at 8:00AM est

Trytosaveabit

Aug 1 06:32

News

$Arbutus Biopharma (ABUS.US)$ Reuters· 1 min ago
Arbutus Biopharma Corp: Prioritizing Imdusiran Phase 2B Clinical Development. Also planning 40% reduction in workforce